Market Overview

Citi Appointed Depositary Bank for AnPac Bio-Medical Science Co., Ltd.'s Sponsored ADR Program

Share:

Citi's Issuer Services, acting through Citibank, N.A., has been appointed by AnPac Bio-Medical Science Co., Ltd. ("Anpac Bio") as the depositary bank for its American Depositary Receipt (ADR) program. Anpac Bio is a leading biotechnology company with operations in China and the United States focused on early cancer screening and detection.

Anpac Bio's program was established in connection with an approximately $16 million initial public offering of its ADRs (exclusive of the over-allotment option), priced at $12.00 per ADR. The ADRs are listed on the NASDAQ Global Market under the symbol "ANPC". Each ADR represents one Class A ordinary share of Anpac Bio. As a single-listed ADR program, the underlying ordinary shares are not listed or publicly traded in the issuer's home market.

"Citi's selection as depositary bank for Anpac Bio's ADR program underscores the depth and breadth of our cross-border capabilities," said Dirk Jones, Head of Global Issuer Services at Citi. "Citi is committed to providing Anpac Bio and its investors with the highest quality ADR services."

Citi is a leading provider of depositary receipt services. With depositary receipt programs in 61 markets, spanning equity and fixed-income products, Citi leverages its global network to provide cross-border capital market access to issuers, intermediaries and investors.

For more information about Citi's Depositary Receipt Services, please visit www.citi.com/dr.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com